Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) were up 2.3% on Thursday . The company traded as high as $9.44 and last traded at $9.25, with a volume of 60,383 shares. The stock had previously closed at $9.04.

A number of analysts have recently weighed in on AQXP shares. Jefferies Group increased their price target on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 21st. Needham & Company LLC initiated coverage on Aquinox Pharmaceuticals in a research report on Thursday, May 12th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $19.86.

The stock’s market capitalization is $160.59 million. The stock’s 50-day moving average price is $8.46 and its 200 day moving average price is $8.38.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. On average, equities research analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.08) earnings per share for the current year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.